PMID- 24503400
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20140207
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 52
IP  - 12
DP  - 2013 Dec
TI  - [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in 
      elderly or drug-intolerable patients with hematologic malignancies].
PG  - 1028-32
AB  - OBJECTIVE: To evaluate the efficacy and safety of modified busulfan (Bu, 9.6 
      mg/kg)/fludarabine (Flu) conditioning regimen on malignant hematologic diseases 
      in elderly and/or drug-intolerable patients. METHODS: We utilized a new reduced 
      intensity conditioning (RIC) containing of new dosage of intravenous Bu (9.6 
      mg/kg), Flu (150 mg/m(2)), cytarabine and semustine but without antithymocyte 
      globulin (ATG) in 23 aged and/or intolerable patients with malignancies. All 23 
      patients, with a median age of 49 (8-66) years, received an allogeneic 
      hematopoietic stem cell transplantation with human leukocyte antigen (HLA) 
      identical sibling donors during January 2008 and January 2012. Stem cells were 
      collected from granulocyte colony-stimulation factor (G-CSF) mobilized bone 
      marrow plus G-CSF mobilized peripheral blood(G-PB) in 20 patients, G-PB alone in 
      two, and non-mobilized BM in one. The graft had a median mononuclear cells (MNC) 
      of 7.03 (4.04-9.9)x10(8)/kg and 1.76 (0.31-6.43)x10(6)/kg of CD(+)34 cells. 
      Graft-versus-host disease (GVHD) prophylaxis included cyclosporin A, 
      mycophenolate mofetil and methotrexate. RESULTS: All patients were well tolerated 
      to the regimen without serious drug related toxicity. Transplant related 
      mortality were 0 and 4.3% at day 100 and one year. All patients except one got 
      full donor engraftment and achieved complete remission. Acute GVHD was observed 
      in 6 patients (26.1%) including grade III-IV in 5 patients. Chronic GVHD was 
      reported in 15 of 21 evaluable patients (71.4%). With a median follow-up of 1138 
      (55-1747) days, 16 of 23 patients were alive and disease-free. Three-year overall 
      survival (OS) and event free survival (EFS) were 79.2% and 69.6%, respectively. 
      CONCLUSION: Modified Bu/Flu as a new RIC regimen is well tolerated and safe for 
      patients who need allogeneic hematopoietic stem cell transplantation, especially 
      in older patients and/or patients with severe comorbidities.
FAU - Wang, Feng-rong
AU  - Wang FR
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Huang, Xiao-jun
AU  - Huang XJ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Liu, Dai-hong
AU  - Liu DH
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Chen, Huan
AU  - Chen H
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Tang, Fei-fei
AU  - Tang FF
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Sun, Yu-qian
AU  - Sun YQ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Fu, Hai-xia
AU  - Fu HX
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Liu, Kai-yan
AU  - Liu KY
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China.
FAU - Xu, Lan-ping
AU  - Xu LP
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing 100044, China. Email: lpxu_0415@sina.com.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - FA2DM6879K (Vidarabine)
RN  - G1LN9045DK (Busulfan)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Busulfan/*administration & dosage
MH  - Child
MH  - Female
MH  - Hematologic Neoplasms/*drug therapy/therapy
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Transplantation Conditioning/*methods
MH  - Vidarabine/administration & dosage/*analogs & derivatives
MH  - Young Adult
EDAT- 2014/02/08 06:00
MHDA- 2015/02/13 06:00
CRDT- 2014/02/08 06:00
PHST- 2014/02/08 06:00 [entrez]
PHST- 2014/02/08 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2013 Dec;52(12):1028-32.